If you are trying to figure out what’s next for Novo Nordisk’s stock, you are definitely not alone. There is a fair amount of chatter lately around where its share price is headed, and with good reason. The stock had a bumpy ride over the past year, down 52.7% in the last 12 months and sitting at 376.95 as of the latest close. But step back a bit, and you see a different story: look five years out, and we’re looking at an 81.7% gain, not to mention a solid 8.2% uptick just in the past month. So, what’s really going on here?

Some of the volatility in recent months can be traced back to global headlines around drug pricing pressures and evolving competition. These developments caused a shift in how investors perceive risk and future reward with Novo Nordisk, amplifying the stock’s short-term swings. Yet despite the dramatic moves, the company’s long-term track record refuses to be ignored. It is no wonder so many investors are wrestling with whether current prices represent a golden opportunity or a potential value trap.

Where does it land on valuation? Novo Nordisk currently boasts a valuation score of 5 out of 6, meaning it checks nearly every box analysts use to identify undervalued stocks. In other words, for those watching for bargains, it is looking pretty appealing right now. Next, let’s break down the key valuation methods in detail. Stick around, because I have an even sharper way to assess Novo Nordisk’s fair value coming up at the end.

Why Novo Nordisk is lagging behind its peers

The Discounted Cash Flow (DCF) model estimates what a company is really worth today by projecting its future cash flows and discounting them back to their present value in DKK. This method helps investors cut through short-term market noise and focus on long-term profitability.

Currently, Novo Nordisk’s Free Cash Flow stands at about DKK 68.4 billion. Analyst estimates forecast this figure to rise steadily, with projections showing DKK 137.2 billion in Free Cash Flow by 2029. For the years beyond 2029, Simply Wall St extrapolates further growth by continuing the trend based on industry expectations and Novo Nordisk’s past performance. All values are provided in Danish Krone (DKK), maintaining consistency with the company’s reporting currency.

According to the DCF model, the intrinsic value of Novo Nordisk’s shares is DKK 1,129.80. With the stock trading at just DKK 376.95, this implies a notable 66.6% discount compared to the model’s fair value estimate. The bottom line is that for those relying on DCF fundamentals, Novo Nordisk is trading well below what long-term projections suggest it is worth.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk.

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 66.6%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is often the go-to metric for valuing established, profitable companies like Novo Nordisk. This metric is particularly relevant because it focuses on actual earnings, providing a clear link between what the company generates and what investors are paying for each krone of profit.

Growth expectations and risk play a major role in what counts as a “normal” or “fair” PE ratio. Typically, companies with higher growth prospects or stability command higher PE multiples. In contrast, more risk or slower growth means investors will want a lower multiple as compensation.

Currently, Novo Nordisk trades on a PE ratio of 15.1x. For context, this is considerably below both the Pharmaceuticals industry average of 24.7x and the peer group average of 27.7x. On the surface, this might suggest that Novo Nordisk is undervalued compared to similar businesses.

This is where Simply Wall St’s proprietary “Fair Ratio” comes in. By factoring in Nova Nordisk’s specific growth outlook, profit margins, industry trends, market cap, and risk profile, the Fair Ratio (28.7x) offers a more tailored benchmark than broad industry or peer averages. The Fair Ratio illustrates what multiple would actually be justified for this unique business today.

Since Novo Nordisk’s actual PE of 15.1x is well below the Fair Ratio of 28.7x, the numbers point to the shares being undervalued by this measure as well.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there’s an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is simply your personal story or perspective on a company, the “why” behind the numbers, where you bring together your beliefs about its future, including assumptions around revenue growth, earnings, profit margins, and what you think is a fair price.

Rather than relying on broad averages or static models, Narratives connect the dots. You build a scenario for Novo Nordisk’s future, see how that shapes a financial forecast, and immediately get an estimated fair value. This takes company analysis beyond abstract models and makes it practical and relevant to your view.

Narratives are easy to use and available right in the Community page on Simply Wall St, empowering millions to crowdsource and compare real investor perspectives. You can see at a glance how your fair value matches the current market price, helping you decide when to buy, hold, or sell. Because Narratives update when fresh news or earnings come out, your view is always grounded in the latest information.

For example, right now investor Narratives on Novo Nordisk range from a fair value of around DKK 444 at the low end to over DKK 1,036 at the high end, showing just how much your story can shape your estimate of what the stock is really worth.

Do you think there's more to the story for Novo Nordisk? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVO B.cpse.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com